학술논문
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Document Type
Article
Author
Trněný, Marek ; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Afanasyev, Boris; Kaplanov, Kamil; Thyss, Antoine; Kuzmin, Alexej; Voloshin, Sergey; Kuliczkowski, Kazimierz; Giza, Agnieszka; Milpied, Noel; Stelitano, Caterina; Marks, Reinhard; Trümper, Lorenz; Biyukov, Tsvetan; Patturajan, Meera; Bravo, Marie-Laure Casadebaig; Arcaini, Luca
Source
In The Lancet Oncology March 2016 17(3):319-331
Subject
Language
ISSN
1470-2045